Vertex Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Raymond Stanley Gross

Mark Thomas Miller

Jinglan Zhou

Andreas Peter Termin

Jason McCartney

Corey Don Anderson

Peter Diederik Jan Grootenhuis

Pramod Virupax Joshi

Thomas Cleveland

Paul Krenitsky

Haripada Khatuya

Johnny Uy

Jeremy J Clemens

Fabrice Jean Denis Pierre

Brian Richard Bear

Vijayalaksmi Arumugam

Hayley Marie Binch

Bryan A Frieman

Timothy Richard Coon

Alina Silina

Gulin Erdogan Marelius

Vito Melillo

Erica Lynn Conroy

Chun-Chieh Lin

Georgia McGaughey Nicholls

Sara Sabina Hadida Ruah

Sara Sabina Hadida-Ruah

Fredrick Van Goor

Robert Michael Hughes

Ali Keshavarz-Shokri

Prasuna Paraselli

David Andrew Siesel

Yi Shi

Kathy Stavropoulos

Paul Angell

Lori Ann Ferris

Muna Shrestha

Alexander Russell Abela

Minson Baek

Anton V Gulevich

Clara Kuang-Ju Hsia

Timothy Alcacio

Ping Kang

Timothy John Young

Keith M Wilcoxen

Richard Christopher Oglesby

Paul John Krenitsky

Jason Mccartney

Paul Timothy Angell

Fredrick F Van Goor

Tomothy John Young

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Modulators of cystic fibrosis transmembrane conductance regulator

Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Methods of making substituted pyrazolopyrimidines generally and, more particularly, N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&#x3b1;]-pyrimidin-7-yl}phenyl)acetamide. Such compounds have utility over a wide range of indications, including treatment of insomnia. In the practice of the present invention, improved techniques which do not require use and/or isolation of the pyrazole intermediate are disclosed, as well as improved techniques for making the reaction intermediates themselves. Such techniques offer significant advantages, including enhanced efficiency, particularly in the context of large scale manufacture.

Synthesis of substituted pyrazolopyrimidines

Methods of making substituted pyrazolopyrimidines generally and, more particularly, N-methyl-N-(3-&lcub;3-&lsqb;2-thienylcarbonyl&rsqb;-pyrazol-&lsqb;1,5-&agr;&rsqb;pyrimidin-7-yl&rcub;phenyl)acetamide. Such compounds have utility over a wide range of indications, including treatment of insomnia. In the practice of the present invention, improved techniques which do not require use and/or isolation of the pyrazole intermediate are disclosed, as well as improved techniques for making the reaction intermediates themselves. Such techniques offer significant advantages, including enhanced efficiency, particularly in the context of large scale manufacture.

Growing community of inventors

Poway, CA, United States of America

Raymond Stanley Gross